Atyra Bio
Atyra Bio is dedicated to improving the quality of life for patients with hypothyroidism, especially those who do not respond well to traditional thyroid hormone therapy. Founded by a thyroid cancer patient, the company aims to develop new drug formulations and companion gene tests to prevent misdiagnosis and optimize treatment, leveraging innovative research and patient involvement.
Industries
Nr. of Employees
small (1-50)
Products
Novel thyroid hormone replacement formulation (in development)
A drug formulation intended to improve symptomatic response in patients who do not feel well on standard thyroid hormone therapy.
Companion gene test (in development)
A genetic test intended to identify individuals at risk of poor symptomatic response to standard thyroid hormone replacement to guide treatment selection.
Novel thyroid hormone replacement formulation (in development)
A drug formulation intended to improve symptomatic response in patients who do not feel well on standard thyroid hormone therapy.
Companion gene test (in development)
A genetic test intended to identify individuals at risk of poor symptomatic response to standard thyroid hormone replacement to guide treatment selection.
Services
Provision or utilization of external research services to support early-stage R&D and hypothesis testing.
Provision or utilization of external research services to support early-stage R&D and hypothesis testing.
Expertise Areas
- Thyroid hormone replacement therapeutics
- Companion diagnostics and genetic testing
- Biomarker discovery and validation
- Early-stage clinical research and patient recruitment
Key Technologies
- Genetic testing / companion diagnostics
- Drug formulation methods
- Biomarker identification and validation assays
- Patient-centered early clinical study methods